Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03083561 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3337641 in Japanese and Caucasian Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03083561 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 36 participants.
The verdict
NCT03083561, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3337641 in healthy Japanese and Caucasian participants. The study will also investigate how the body processes LY3337641 and the effect of LY3337641 on the body. The study will last up to 4 weeks for each participant. Screening may occur within 28 days prior to first dose of study drug.
Interventions
- DRUG Placebo
- DRUG LY3337641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2017-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03083561
The ClinicalTrials.gov registry entry for NCT03083561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03083561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03083561 about?
NCT03083561 is a clinical study titled "A Study of LY3337641 in Japanese and Caucasian Healthy Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3337641 in healthy Japanese and Caucasian participants. The study will also investigate how the body processes LY3337641 and the effect of LY3337641 on the body. The study will last up to 4 weeks for each participant. Scr...
What is the current status of trial NCT03083561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2017-03-15. Estimated completion is 2017-05-25.
What interventions are being tested in trial NCT03083561?
The interventions under investigation include: Placebo (DRUG), LY3337641 (DRUG).
Who is sponsoring clinical trial NCT03083561?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.